#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=4 .
1-1	0-1	4	quantity	new	_	_
1-2	2-3	.	_	_	_	_

#Text=Discussion
2-1	4-14	Discussion	abstract	new	_	_

#Text=We found bilateral hypersensitivity to pressure pain within the temporalis muscle in men with episodic CH not to be associated with levels of anxiety or depression .
3-1	15-17	We	person	acc	ana	4-3
3-2	18-23	found	_	_	_	_
3-3	24-33	bilateral	abstract[4]	new[4]	coref	6-9[32_4]
3-4	34-50	hypersensitivity	abstract[4]	new[4]	_	_
3-5	51-53	to	_	_	_	_
3-6	54-62	pressure	_	_	_	_
3-7	63-67	pain	abstract	new	coref	4-14
3-8	68-74	within	_	_	_	_
3-9	75-78	the	object[6]	new[6]	coref	10-8[65_6]
3-10	79-89	temporalis	object[6]	new[6]	_	_
3-11	90-96	muscle	object[6]	new[6]	_	_
3-12	97-99	in	object[6]	new[6]	_	_
3-13	100-103	men	object[6]|person[7]	new[6]|new[7]	coref	4-16[17_7]
3-14	104-108	with	object[6]|person[7]	new[6]|new[7]	_	_
3-15	109-117	episodic	object[6]|person[7]|abstract[8]	new[6]|new[7]|new[8]	coref	4-18[0_8]
3-16	118-120	CH	object[6]|person[7]|abstract[8]	new[6]|new[7]|new[8]	_	_
3-17	121-124	not	_	_	_	_
3-18	125-127	to	_	_	_	_
3-19	128-130	be	_	_	_	_
3-20	131-141	associated	_	_	_	_
3-21	142-146	with	_	_	_	_
3-22	147-153	levels	abstract[9]	new[9]	_	_
3-23	154-156	of	abstract[9]	new[9]	_	_
3-24	157-164	anxiety	abstract[9]|abstract	new[9]|new	_	_
3-25	165-167	or	abstract[9]	new[9]	_	_
3-26	168-178	depression	abstract[9]|abstract	new[9]|new	_	_
3-27	179-180	.	_	_	_	_

#Text=Additionally , our mapping revealed a spatial anterior-to-posterior gradient of sensitivity to pressure pain in men with CH but not in headache-free controls .
4-1	181-193	Additionally	_	_	_	_
4-2	194-195	,	_	_	_	_
4-3	196-199	our	person|abstract[13]	giv|new[13]	ana|coref|ana|coref	5-4|17-1[115_13]|5-4|17-1[115_13]
4-4	200-207	mapping	abstract[13]	new[13]	_	_
4-5	208-216	revealed	_	_	_	_
4-6	217-218	a	abstract[14]	new[14]	_	_
4-7	219-226	spatial	abstract[14]	new[14]	_	_
4-8	227-248	anterior-to-posterior	abstract[14]	new[14]	_	_
4-9	249-257	gradient	abstract[14]	new[14]	_	_
4-10	258-260	of	abstract[14]	new[14]	_	_
4-11	261-272	sensitivity	abstract[14]|abstract	new[14]|new	coref	17-3
4-12	273-275	to	_	_	_	_
4-13	276-284	pressure	_	_	_	_
4-14	285-289	pain	abstract	giv	coref	6-12
4-15	290-292	in	_	_	_	_
4-16	293-296	men	person[17]	giv[17]	coref	5-15[24_17]
4-17	297-301	with	person[17]	giv[17]	_	_
4-18	302-304	CH	person[17]|abstract	giv[17]|giv	coref	5-17
4-19	305-308	but	_	_	_	_
4-20	309-312	not	_	_	_	_
4-21	313-315	in	_	_	_	_
4-22	316-329	headache-free	person[19]	new[19]	coref	5-20[26_19]
4-23	330-338	controls	person[19]	new[19]	_	_
4-24	339-340	.	_	_	_	_

#Text=In line with our hypothesis , there was a bilateral decrease of PPTs in men with CH compared with controls with large effect sizes .
5-1	341-343	In	_	_	_	_
5-2	344-348	line	_	_	_	_
5-3	349-353	with	_	_	_	_
5-4	354-357	our	person|abstract[21]	giv|new[21]	ana|ana	6-1|6-1
5-5	358-368	hypothesis	abstract[21]	new[21]	_	_
5-6	369-370	,	_	_	_	_
5-7	371-376	there	_	_	_	_
5-8	377-380	was	_	_	_	_
5-9	381-382	a	event[22]	new[22]	_	_
5-10	383-392	bilateral	event[22]	new[22]	_	_
5-11	393-401	decrease	event[22]	new[22]	_	_
5-12	402-404	of	event[22]	new[22]	_	_
5-13	405-409	PPTs	event[22]|abstract	new[22]|new	coref	16-15
5-14	410-412	in	event[22]	new[22]	_	_
5-15	413-416	men	event[22]|person[24]	new[22]|giv[24]	_	_
5-16	417-421	with	event[22]|person[24]	new[22]|giv[24]	_	_
5-17	422-424	CH	event[22]|person[24]|abstract	new[22]|giv[24]|giv	coref	6-21
5-18	425-433	compared	_	_	_	_
5-19	434-438	with	_	_	_	_
5-20	439-447	controls	person[26]	giv[26]	coref	20-7[140_26]
5-21	448-452	with	person[26]	giv[26]	_	_
5-22	453-458	large	person[26]|abstract[28]	giv[26]|new[28]	ana	6-5[0_28]
5-23	459-465	effect	person[26]|abstract|abstract[28]	giv[26]|new|new[28]	_	_
5-24	466-471	sizes	person[26]|abstract[28]	giv[26]|new[28]	_	_
5-25	472-473	.	_	_	_	_

#Text=Our results agree with those previously reported where bilateral hypersensitivity to pain pressure in the temporalis area in patients with CH was also observed .
6-1	474-477	Our	person|abstract[30]	giv|new[30]	coref|ana|coref|ana	7-3[39_30]|11-1|7-3[39_30]|11-1
6-2	478-485	results	abstract[30]	new[30]	_	_
6-3	486-491	agree	_	_	_	_
6-4	492-496	with	_	_	_	_
6-5	497-502	those	abstract	giv	_	_
6-6	503-513	previously	_	_	_	_
6-7	514-522	reported	_	_	_	_
6-8	523-528	where	_	_	_	_
6-9	529-538	bilateral	abstract[32]	giv[32]	coref	10-24[68_32]
6-10	539-555	hypersensitivity	abstract[32]	giv[32]	_	_
6-11	556-558	to	abstract[32]	giv[32]	_	_
6-12	559-563	pain	abstract[32]|abstract|abstract[34]	giv[32]|giv|new[34]	coref|coref|coref|coref	8-13|9-8[0_34]|8-13|9-8[0_34]
6-13	564-572	pressure	abstract[32]|abstract[34]	giv[32]|new[34]	_	_
6-14	573-575	in	abstract[32]|abstract[34]	giv[32]|new[34]	_	_
6-15	576-579	the	abstract[32]|abstract[34]|place[36]	giv[32]|new[34]|new[36]	coref	12-7[80_36]
6-16	580-590	temporalis	abstract[32]|abstract[34]|abstract|place[36]	giv[32]|new[34]|new|new[36]	coref	10-9
6-17	591-595	area	abstract[32]|abstract[34]|place[36]	giv[32]|new[34]|new[36]	_	_
6-18	596-598	in	abstract[32]|abstract[34]|place[36]	giv[32]|new[34]|new[36]	_	_
6-19	599-607	patients	abstract[32]|abstract[34]|place[36]|person[37]	giv[32]|new[34]|new[36]|new[37]	coref	7-32[44_37]
6-20	608-612	with	abstract[32]|abstract[34]|place[36]|person[37]	giv[32]|new[34]|new[36]|new[37]	_	_
6-21	613-615	CH	abstract[32]|abstract[34]|place[36]|person[37]|abstract	giv[32]|new[34]|new[36]|new[37]|giv	coref	7-34
6-22	616-619	was	_	_	_	_
6-23	620-624	also	_	_	_	_
6-24	625-633	observed	_	_	_	_
6-25	634-635	.	_	_	_	_

#Text=However , these results differ from those reported by Malo-Urriés et al. , who observed that the symptomatic side was more sensitive than the non-symptomatic side in a small sample of patients with CH .
7-1	636-643	However	_	_	_	_
7-2	644-645	,	_	_	_	_
7-3	646-651	these	abstract[39]	giv[39]	coref	21-1[143_39]
7-4	652-659	results	abstract[39]	giv[39]	_	_
7-5	660-666	differ	_	_	_	_
7-6	667-671	from	_	_	_	_
7-7	672-677	those	_	_	_	_
7-8	678-686	reported	_	_	_	_
7-9	687-689	by	_	_	_	_
7-10	690-701	Malo-Urriés	person	new	_	_
7-11	702-704	et	_	_	_	_
7-12	705-708	al.	_	_	_	_
7-13	709-710	,	_	_	_	_
7-14	711-714	who	_	_	_	_
7-15	715-723	observed	_	_	_	_
7-16	724-728	that	_	_	_	_
7-17	729-732	the	abstract[41]	new[41]	_	_
7-18	733-744	symptomatic	abstract[41]	new[41]	_	_
7-19	745-749	side	abstract[41]	new[41]	_	_
7-20	750-753	was	_	_	_	_
7-21	754-758	more	_	_	_	_
7-22	759-768	sensitive	_	_	_	_
7-23	769-773	than	_	_	_	_
7-24	774-777	the	abstract[42]	new[42]	_	_
7-25	778-793	non-symptomatic	abstract[42]	new[42]	_	_
7-26	794-798	side	abstract[42]	new[42]	_	_
7-27	799-801	in	abstract[42]	new[42]	_	_
7-28	802-803	a	abstract[42]|person[43]	new[42]|new[43]	_	_
7-29	804-809	small	abstract[42]|person[43]	new[42]|new[43]	_	_
7-30	810-816	sample	abstract[42]|person[43]	new[42]|new[43]	_	_
7-31	817-819	of	abstract[42]|person[43]	new[42]|new[43]	_	_
7-32	820-828	patients	abstract[42]|person[43]|person[44]	new[42]|new[43]|giv[44]	coref	8-16[52_44]
7-33	829-833	with	abstract[42]|person[43]|person[44]	new[42]|new[43]|giv[44]	_	_
7-34	834-836	CH	abstract[42]|person[43]|person[44]|abstract	new[42]|new[43]|giv[44]|giv	coref	8-16
7-35	837-838	.	_	_	_	_

#Text=The current and previous findings suggest the presence of sensitization of trigeminal pain pathways in CH patients .
8-1	839-842	The	abstract[46]	new[46]	coref	13-1[84_46]
8-2	843-850	current	abstract[46]	new[46]	_	_
8-3	851-854	and	abstract[46]	new[46]	_	_
8-4	855-863	previous	abstract[46]	new[46]	_	_
8-5	864-872	findings	abstract[46]	new[46]	_	_
8-6	873-880	suggest	_	_	_	_
8-7	881-884	the	abstract[47]	new[47]	_	_
8-8	885-893	presence	abstract[47]	new[47]	_	_
8-9	894-896	of	abstract[47]	new[47]	_	_
8-10	897-910	sensitization	abstract[47]|abstract[48]	new[47]|new[48]	_	_
8-11	911-913	of	abstract[47]|abstract[48]	new[47]|new[48]	_	_
8-12	914-924	trigeminal	abstract[47]|abstract[48]|place[50]	new[47]|new[48]|new[50]	coref	24-5[156_50]
8-13	925-929	pain	abstract[47]|abstract[48]|abstract|place[50]	new[47]|new[48]|giv|new[50]	coref	9-9
8-14	930-938	pathways	abstract[47]|abstract[48]|place[50]	new[47]|new[48]|new[50]	_	_
8-15	939-941	in	abstract[47]|abstract[48]|place[50]	new[47]|new[48]|new[50]	_	_
8-16	942-944	CH	abstract[47]|abstract[48]|place[50]|abstract|person[52]	new[47]|new[48]|new[50]|giv|giv[52]	coref|coref|coref|coref	9-12[57_52]|12-17|9-12[57_52]|12-17
8-17	945-953	patients	abstract[47]|abstract[48]|place[50]|person[52]	new[47]|new[48]|new[50]|giv[52]	_	_
8-18	954-955	.	_	_	_	_

#Text=In addition , the presence of bilateral pressure pain hyperalgesia in patients with unilateral symptoms supports potential sensitization of the central nervous system , as previously suggested , although further studies are needed .
9-1	956-958	In	_	_	_	_
9-2	959-967	addition	_	_	_	_
9-3	968-969	,	_	_	_	_
9-4	970-973	the	abstract[53]	new[53]	_	_
9-5	974-982	presence	abstract[53]	new[53]	_	_
9-6	983-985	of	abstract[53]	new[53]	_	_
9-7	986-995	bilateral	abstract[53]|abstract[56]	new[53]|new[56]	coref	10-3[62_56]
9-8	996-1004	pressure	abstract[53]|abstract|abstract[56]	new[53]|giv|new[56]	coref	10-6[63_0]
9-9	1005-1009	pain	abstract[53]|abstract|abstract[56]	new[53]|giv|new[56]	coref	12-4
9-10	1010-1022	hyperalgesia	abstract[53]|abstract[56]	new[53]|new[56]	_	_
9-11	1023-1025	in	abstract[53]|abstract[56]	new[53]|new[56]	_	_
9-12	1026-1034	patients	abstract[53]|abstract[56]|person[57]	new[53]|new[56]|giv[57]	coref	10-16[66_57]
9-13	1035-1039	with	abstract[53]|abstract[56]|person[57]	new[53]|new[56]|giv[57]	_	_
9-14	1040-1050	unilateral	abstract[53]|abstract[56]|person[57]|abstract[58]	new[53]|new[56]|giv[57]|new[58]	coref	10-32[70_58]
9-15	1051-1059	symptoms	abstract[53]|abstract[56]|person[57]|abstract[58]	new[53]|new[56]|giv[57]|new[58]	_	_
9-16	1060-1068	supports	_	_	_	_
9-17	1069-1078	potential	abstract[59]	new[59]	coref	13-11[86_59]
9-18	1079-1092	sensitization	abstract[59]	new[59]	_	_
9-19	1093-1095	of	abstract[59]	new[59]	_	_
9-20	1096-1099	the	abstract[59]|object[60]	new[59]|new[60]	_	_
9-21	1100-1107	central	abstract[59]|object[60]	new[59]|new[60]	_	_
9-22	1108-1115	nervous	abstract[59]|object[60]	new[59]|new[60]	_	_
9-23	1116-1122	system	abstract[59]|object[60]	new[59]|new[60]	_	_
9-24	1123-1124	,	_	_	_	_
9-25	1125-1127	as	_	_	_	_
9-26	1128-1138	previously	_	_	_	_
9-27	1139-1148	suggested	_	_	_	_
9-28	1149-1150	,	_	_	_	_
9-29	1151-1159	although	_	_	_	_
9-30	1160-1167	further	event[61]	new[61]	coref	25-36[174_61]
9-31	1168-1175	studies	event[61]	new[61]	_	_
9-32	1176-1179	are	_	_	_	_
9-33	1180-1186	needed	_	_	_	_
9-34	1187-1188	.	_	_	_	_

#Text=Similarly , bilateral hyperalgesia to pressure over the temporalis muscle has previously been found in patients with strictly unilateral migraine , suggesting that bilateral hypersensitivity is present albeit the presence of just unilateral symptoms in individuals with primary headaches .
10-1	1189-1198	Similarly	_	_	_	_
10-2	1199-1200	,	_	_	_	_
10-3	1201-1210	bilateral	abstract[62]	giv[62]	coref	12-3[79_62]
10-4	1211-1223	hyperalgesia	abstract[62]	giv[62]	_	_
10-5	1224-1226	to	abstract[62]	giv[62]	_	_
10-6	1227-1235	pressure	abstract[62]|abstract[63]	giv[62]|giv[63]	coref	12-3[0_63]
10-7	1236-1240	over	abstract[62]|abstract[63]	giv[62]|giv[63]	_	_
10-8	1241-1244	the	abstract[62]|abstract[63]|object[65]	giv[62]|giv[63]|giv[65]	coref	19-18[134_65]
10-9	1245-1255	temporalis	abstract[62]|abstract[63]|object|object[65]	giv[62]|giv[63]|giv|giv[65]	_	_
10-10	1256-1262	muscle	abstract[62]|abstract[63]|object[65]	giv[62]|giv[63]|giv[65]	_	_
10-11	1263-1266	has	_	_	_	_
10-12	1267-1277	previously	_	_	_	_
10-13	1278-1282	been	_	_	_	_
10-14	1283-1288	found	_	_	_	_
10-15	1289-1291	in	_	_	_	_
10-16	1292-1300	patients	person[66]	giv[66]	coref	11-1[74_66]
10-17	1301-1305	with	person[66]	giv[66]	_	_
10-18	1306-1314	strictly	person[66]|abstract[67]	giv[66]|new[67]	coref	21-22[149_67]
10-19	1315-1325	unilateral	person[66]|abstract[67]	giv[66]|new[67]	_	_
10-20	1326-1334	migraine	person[66]|abstract[67]	giv[66]|new[67]	_	_
10-21	1335-1336	,	_	_	_	_
10-22	1337-1347	suggesting	_	_	_	_
10-23	1348-1352	that	_	_	_	_
10-24	1353-1362	bilateral	abstract[68]	giv[68]	_	_
10-25	1363-1379	hypersensitivity	abstract[68]	giv[68]	_	_
10-26	1380-1382	is	_	_	_	_
10-27	1383-1390	present	_	_	_	_
10-28	1391-1397	albeit	_	_	_	_
10-29	1398-1401	the	abstract[69]	new[69]	_	_
10-30	1402-1410	presence	abstract[69]	new[69]	_	_
10-31	1411-1413	of	abstract[69]	new[69]	_	_
10-32	1414-1418	just	abstract[69]|abstract[70]	new[69]|giv[70]	coref	24-29[163_70]
10-33	1419-1429	unilateral	abstract[69]|abstract[70]	new[69]|giv[70]	_	_
10-34	1430-1438	symptoms	abstract[69]|abstract[70]	new[69]|giv[70]	_	_
10-35	1439-1441	in	abstract[69]|abstract[70]	new[69]|giv[70]	_	_
10-36	1442-1453	individuals	abstract[69]|abstract[70]|person	new[69]|giv[70]|new	coref	29-26[211_0]
10-37	1454-1458	with	abstract[69]|abstract[70]	new[69]|giv[70]	_	_
10-38	1459-1466	primary	abstract[69]|abstract[70]|abstract[72]	new[69]|giv[70]|new[72]	coref	15-16[103_72]
10-39	1467-1476	headaches	abstract[69]|abstract[70]|abstract[72]	new[69]|giv[70]|new[72]	_	_
10-40	1477-1478	.	_	_	_	_

#Text=Our patients were assessed during a long-lasting remission phase .
11-1	1479-1482	Our	person|person[74]	giv|giv[74]	coref|ana|coref|ana	12-15[81_74]|16-3|12-15[81_74]|16-3
11-2	1483-1491	patients	person[74]	giv[74]	_	_
11-3	1492-1496	were	_	_	_	_
11-4	1497-1505	assessed	_	_	_	_
11-5	1506-1512	during	_	_	_	_
11-6	1513-1514	a	abstract[76]	new[76]	coref	14-33[99_76]
11-7	1515-1527	long-lasting	abstract[76]	new[76]	_	_
11-8	1528-1537	remission	abstract|abstract[76]	new|new[76]	coref	14-34
11-9	1538-1543	phase	abstract[76]	new[76]	_	_
11-10	1544-1545	.	_	_	_	_

#Text=Therefore , pressure pain hyperalgesia in the trigeminal area seems to be present in patients with CH during asymptomatic periods .
12-1	1546-1555	Therefore	_	_	_	_
12-2	1556-1557	,	_	_	_	_
12-3	1558-1566	pressure	abstract|abstract[79]	giv|giv[79]	coref|coref|coref|coref	18-9[122_0]|26-22[182_79]|18-9[122_0]|26-22[182_79]
12-4	1567-1571	pain	abstract|abstract[79]	giv|giv[79]	coref	13-19
12-5	1572-1584	hyperalgesia	abstract[79]	giv[79]	_	_
12-6	1585-1587	in	abstract[79]	giv[79]	_	_
12-7	1588-1591	the	abstract[79]|place[80]	giv[79]|giv[80]	coref	19-30[137_80]
12-8	1592-1602	trigeminal	abstract[79]|place[80]	giv[79]|giv[80]	_	_
12-9	1603-1607	area	abstract[79]|place[80]	giv[79]|giv[80]	_	_
12-10	1608-1613	seems	_	_	_	_
12-11	1614-1616	to	_	_	_	_
12-12	1617-1619	be	_	_	_	_
12-13	1620-1627	present	_	_	_	_
12-14	1628-1630	in	_	_	_	_
12-15	1631-1639	patients	person[81]	giv[81]	coref	18-15[126_81]
12-16	1640-1644	with	person[81]	giv[81]	_	_
12-17	1645-1647	CH	person[81]|abstract	giv[81]|giv	coref	13-14
12-18	1648-1654	during	_	_	_	_
12-19	1655-1667	asymptomatic	abstract[83]	new[83]	coref	13-17[88_83]
12-20	1668-1675	periods	abstract[83]	new[83]	_	_
12-21	1676-1677	.	_	_	_	_

#Text=These findings indicate that there is a baseline state of trigeminal sensitization in CH predisposing to periods of pain .
13-1	1678-1683	These	abstract[84]	giv[84]	coref	19-3[129_84]
13-2	1684-1692	findings	abstract[84]	giv[84]	_	_
13-3	1693-1701	indicate	_	_	_	_
13-4	1702-1706	that	_	_	_	_
13-5	1707-1712	there	_	_	_	_
13-6	1713-1715	is	_	_	_	_
13-7	1716-1717	a	abstract[85]	new[85]	_	_
13-8	1718-1726	baseline	abstract[85]	new[85]	_	_
13-9	1727-1732	state	abstract[85]	new[85]	_	_
13-10	1733-1735	of	abstract[85]	new[85]	_	_
13-11	1736-1746	trigeminal	abstract[85]|abstract[86]	new[85]|giv[86]	coref	16-9[106_86]
13-12	1747-1760	sensitization	abstract[85]|abstract[86]	new[85]|giv[86]	_	_
13-13	1761-1763	in	abstract[85]|abstract[86]	new[85]|giv[86]	_	_
13-14	1764-1766	CH	abstract[85]|abstract[86]|abstract	new[85]|giv[86]|giv	coref	16-12
13-15	1767-1779	predisposing	_	_	_	_
13-16	1780-1782	to	_	_	_	_
13-17	1783-1790	periods	abstract[88]	giv[88]	_	_
13-18	1791-1793	of	abstract[88]	giv[88]	_	_
13-19	1794-1798	pain	abstract[88]|abstract	giv[88]|giv	coref	17-2
13-20	1799-1800	.	_	_	_	_

#Text=Alternatively , it is also possible that the altered nociceptive processing could be induced by repetitive headache attacks of high intensity and then maintained without the presence of any nociceptive stimuli during the remission phase .
14-1	1801-1814	Alternatively	_	_	_	_
14-2	1815-1816	,	_	_	_	_
14-3	1817-1819	it	abstract	new	cata	14-3[0_92]
14-4	1820-1822	is	_	_	_	_
14-5	1823-1827	also	_	_	_	_
14-6	1828-1836	possible	_	_	_	_
14-7	1837-1841	that	abstract[92]	new[92]	_	_
14-8	1842-1845	the	abstract[91]|abstract[92]	new[91]|new[92]	_	_
14-9	1846-1853	altered	abstract[91]|abstract[92]	new[91]|new[92]	_	_
14-10	1854-1865	nociceptive	abstract[91]|abstract[92]	new[91]|new[92]	_	_
14-11	1866-1876	processing	abstract[91]|abstract[92]	new[91]|new[92]	_	_
14-12	1877-1882	could	abstract[92]	new[92]	_	_
14-13	1883-1885	be	abstract[92]	new[92]	_	_
14-14	1886-1893	induced	abstract[92]	new[92]	_	_
14-15	1894-1896	by	_	_	_	_
14-16	1897-1907	repetitive	event[94]	new[94]	_	_
14-17	1908-1916	headache	abstract|event[94]	new|new[94]	coref	21-19[148_0]
14-18	1917-1924	attacks	event[94]	new[94]	_	_
14-19	1925-1927	of	event[94]	new[94]	_	_
14-20	1928-1932	high	event[94]|abstract[95]	new[94]|new[95]	_	_
14-21	1933-1942	intensity	event[94]|abstract[95]	new[94]|new[95]	_	_
14-22	1943-1946	and	_	_	_	_
14-23	1947-1951	then	_	_	_	_
14-24	1952-1962	maintained	_	_	_	_
14-25	1963-1970	without	_	_	_	_
14-26	1971-1974	the	abstract[96]	new[96]	_	_
14-27	1975-1983	presence	abstract[96]	new[96]	_	_
14-28	1984-1986	of	abstract[96]	new[96]	_	_
14-29	1987-1990	any	abstract[96]|abstract[97]	new[96]|new[97]	coref	15-10[102_97]
14-30	1991-2002	nociceptive	abstract[96]|abstract[97]	new[96]|new[97]	_	_
14-31	2003-2010	stimuli	abstract[96]|abstract[97]	new[96]|new[97]	_	_
14-32	2011-2017	during	abstract[96]|abstract[97]	new[96]|new[97]	_	_
14-33	2018-2021	the	abstract[96]|abstract[97]|abstract[99]	new[96]|new[97]|giv[99]	coref	31-14[222_99]
14-34	2022-2031	remission	abstract[96]|abstract[97]|abstract|abstract[99]	new[96]|new[97]|giv|giv[99]	coref	31-15
14-35	2032-2037	phase	abstract[96]|abstract[97]|abstract[99]	new[96]|new[97]|giv[99]	_	_
14-36	2038-2039	.	_	_	_	_

#Text=Indeed , the occurrence of long-term potentiation induced by nociceptive stimuli has been suggested in other primary headaches .
15-1	2040-2046	Indeed	_	_	_	_
15-2	2047-2048	,	_	_	_	_
15-3	2049-2052	the	abstract[100]	new[100]	_	_
15-4	2053-2063	occurrence	abstract[100]	new[100]	_	_
15-5	2064-2066	of	abstract[100]	new[100]	_	_
15-6	2067-2076	long-term	abstract[100]|abstract[101]	new[100]|new[101]	_	_
15-7	2077-2089	potentiation	abstract[100]|abstract[101]	new[100]|new[101]	_	_
15-8	2090-2097	induced	_	_	_	_
15-9	2098-2100	by	_	_	_	_
15-10	2101-2112	nociceptive	abstract[102]	giv[102]	_	_
15-11	2113-2120	stimuli	abstract[102]	giv[102]	_	_
15-12	2121-2124	has	_	_	_	_
15-13	2125-2129	been	_	_	_	_
15-14	2130-2139	suggested	_	_	_	_
15-15	2140-2142	in	_	_	_	_
15-16	2143-2148	other	abstract[103]	giv[103]	coref	21-13[146_103]
15-17	2149-2156	primary	abstract[103]	giv[103]	_	_
15-18	2157-2166	headaches	abstract[103]	giv[103]	_	_
15-19	2167-2168	.	_	_	_	_

#Text=However , we cannot confirm the presence of central sensitization in CH , since PPTs represent a static outcome and dynamic measures of nociception would be needed .
16-1	2169-2176	However	_	_	_	_
16-2	2177-2178	,	_	_	_	_
16-3	2179-2181	we	person	giv	ana	19-3
16-4	2182-2188	cannot	_	_	_	_
16-5	2189-2196	confirm	_	_	_	_
16-6	2197-2200	the	abstract[105]	new[105]	_	_
16-7	2201-2209	presence	abstract[105]	new[105]	_	_
16-8	2210-2212	of	abstract[105]	new[105]	_	_
16-9	2213-2220	central	abstract[105]|abstract[106]	new[105]|giv[106]	_	_
16-10	2221-2234	sensitization	abstract[105]|abstract[106]	new[105]|giv[106]	_	_
16-11	2235-2237	in	abstract[105]|abstract[106]	new[105]|giv[106]	_	_
16-12	2238-2240	CH	abstract[105]|abstract[106]|abstract	new[105]|giv[106]|giv	coref	18-17[127_0]
16-13	2241-2242	,	_	_	_	_
16-14	2243-2248	since	_	_	_	_
16-15	2249-2253	PPTs	abstract	giv	_	_
16-16	2254-2263	represent	_	_	_	_
16-17	2264-2265	a	abstract[109]	new[109]	_	_
16-18	2266-2272	static	abstract[109]	new[109]	_	_
16-19	2273-2280	outcome	abstract[109]	new[109]	_	_
16-20	2281-2284	and	_	_	_	_
16-21	2285-2292	dynamic	abstract[110]	new[110]	_	_
16-22	2293-2301	measures	abstract[110]	new[110]	_	_
16-23	2302-2304	of	abstract[110]	new[110]	_	_
16-24	2305-2316	nociception	abstract[110]|abstract	new[110]|new	_	_
16-25	2317-2322	would	_	_	_	_
16-26	2323-2325	be	_	_	_	_
16-27	2326-2332	needed	_	_	_	_
16-28	2333-2334	.	_	_	_	_

#Text=Pressure pain sensitivity mapping based on multi-site recordings has previously been documented as a useful technique for visualizing the spatial topographic distribution of pain sensitivity .
17-1	2335-2343	Pressure	person|abstract[115]	new|giv[115]	_	_
17-2	2344-2348	pain	abstract|abstract[115]	giv|giv[115]	coref	17-24
17-3	2349-2360	sensitivity	abstract|abstract[115]	giv|giv[115]	coref	17-24[119_0]
17-4	2361-2368	mapping	abstract[115]	giv[115]	_	_
17-5	2369-2374	based	_	_	_	_
17-6	2375-2377	on	_	_	_	_
17-7	2378-2388	multi-site	abstract[116]	new[116]	_	_
17-8	2389-2399	recordings	abstract[116]	new[116]	_	_
17-9	2400-2403	has	_	_	_	_
17-10	2404-2414	previously	_	_	_	_
17-11	2415-2419	been	_	_	_	_
17-12	2420-2430	documented	_	_	_	_
17-13	2431-2433	as	_	_	_	_
17-14	2434-2435	a	_	_	_	_
17-15	2436-2442	useful	_	_	_	_
17-16	2443-2452	technique	_	_	_	_
17-17	2453-2456	for	_	_	_	_
17-18	2457-2468	visualizing	_	_	_	_
17-19	2469-2472	the	abstract[117]	new[117]	coref	24-15[160_117]
17-20	2473-2480	spatial	abstract[117]	new[117]	_	_
17-21	2481-2492	topographic	abstract[117]	new[117]	_	_
17-22	2493-2505	distribution	abstract[117]	new[117]	_	_
17-23	2506-2508	of	abstract[117]	new[117]	_	_
17-24	2509-2513	pain	abstract[117]|abstract|abstract[119]	new[117]|giv|giv[119]	coref|coref|coref|coref	18-11|18-12[0_119]|18-11|18-12[0_119]
17-25	2514-2525	sensitivity	abstract[117]|abstract[119]	new[117]|giv[119]	_	_
17-26	2526-2527	.	_	_	_	_

#Text=This study is the first attempt at assessing topographical pressure pain sensitivity maps in patients with episodic CH .
18-1	2528-2532	This	abstract[120]	new[120]	coref	18-4[121_120]
18-2	2533-2538	study	abstract[120]	new[120]	_	_
18-3	2539-2541	is	_	_	_	_
18-4	2542-2545	the	abstract[121]	giv[121]	coref	21-4[144_121]
18-5	2546-2551	first	abstract[121]	giv[121]	_	_
18-6	2552-2559	attempt	abstract[121]	giv[121]	_	_
18-7	2560-2562	at	_	_	_	_
18-8	2563-2572	assessing	_	_	_	_
18-9	2573-2586	topographical	abstract[122]	giv[122]	coref	24-10[0_122]
18-10	2587-2595	pressure	abstract[122]	giv[122]	_	_
18-11	2596-2600	pain	abstract|object[125]	giv|new[125]	coref|coref|coref|coref	19-25|35-10[257_125]|19-25|35-10[257_125]
18-12	2601-2612	sensitivity	abstract|object[125]	giv|new[125]	coref	19-16[133_0]
18-13	2613-2617	maps	object[125]	new[125]	_	_
18-14	2618-2620	in	object[125]	new[125]	_	_
18-15	2621-2629	patients	object[125]|person[126]	new[125]|giv[126]	coref	19-7[131_126]
18-16	2630-2634	with	object[125]|person[126]	new[125]|giv[126]	_	_
18-17	2635-2643	episodic	object[125]|person[126]|abstract[127]	new[125]|giv[126]|giv[127]	coref	19-7[0_127]
18-18	2644-2646	CH	object[125]|person[126]|abstract[127]	new[125]|giv[126]|giv[127]	_	_
18-19	2647-2648	.	_	_	_	_

#Text=According to our findings , in CH patients , there is an anterior-to-posterior gradient of sensitivity within the temporalis muscle so that the lowest pain thresholds are located in the anterior region of the muscle .
19-1	2649-2658	According	_	_	_	_
19-2	2659-2661	to	_	_	_	_
19-3	2662-2665	our	person|abstract[129]	giv|giv[129]	ana|ana	26-3|26-3
19-4	2666-2674	findings	abstract[129]	giv[129]	_	_
19-5	2675-2676	,	abstract[129]	giv[129]	_	_
19-6	2677-2679	in	abstract[129]	giv[129]	_	_
19-7	2680-2682	CH	abstract[129]|abstract|person[131]	giv[129]|giv|giv[131]	coref|coref	26-32[185_0]|26-32[185_0]
19-8	2683-2691	patients	abstract[129]|person[131]	giv[129]|giv[131]	_	_
19-9	2692-2693	,	_	_	_	_
19-10	2694-2699	there	_	_	_	_
19-11	2700-2702	is	_	_	_	_
19-12	2703-2705	an	abstract[132]	new[132]	coref	20-1[139_132]
19-13	2706-2727	anterior-to-posterior	abstract[132]	new[132]	_	_
19-14	2728-2736	gradient	abstract[132]	new[132]	_	_
19-15	2737-2739	of	abstract[132]	new[132]	_	_
19-16	2740-2751	sensitivity	abstract[132]|abstract[133]	new[132]|giv[133]	coref	27-18[190_133]
19-17	2752-2758	within	abstract[132]|abstract[133]	new[132]|giv[133]	_	_
19-18	2759-2762	the	abstract[132]|abstract[133]|object[134]	new[132]|giv[133]|giv[134]	coref	19-34[138_134]
19-19	2763-2773	temporalis	abstract[132]|abstract[133]|object[134]	new[132]|giv[133]|giv[134]	_	_
19-20	2774-2780	muscle	abstract[132]|abstract[133]|object[134]	new[132]|giv[133]|giv[134]	_	_
19-21	2781-2783	so	_	_	_	_
19-22	2784-2788	that	_	_	_	_
19-23	2789-2792	the	abstract[136]	new[136]	ana	21-9[0_136]
19-24	2793-2799	lowest	abstract[136]	new[136]	_	_
19-25	2800-2804	pain	abstract|abstract[136]	giv|new[136]	coref	24-11
19-26	2805-2815	thresholds	abstract[136]	new[136]	_	_
19-27	2816-2819	are	_	_	_	_
19-28	2820-2827	located	_	_	_	_
19-29	2828-2830	in	_	_	_	_
19-30	2831-2834	the	place[137]	giv[137]	coref	20-11[141_137]
19-31	2835-2843	anterior	place[137]	giv[137]	_	_
19-32	2844-2850	region	place[137]	giv[137]	_	_
19-33	2851-2853	of	place[137]	giv[137]	_	_
19-34	2854-2857	the	place[137]|object[138]	giv[137]|giv[138]	coref	25-14[0_138]
19-35	2858-2864	muscle	place[137]|object[138]	giv[137]|giv[138]	_	_
19-36	2865-2866	.	_	_	_	_

#Text=This gradient is not present in headache-free controls , where the most sensitive area was located in the mid-muscle belly .
20-1	2867-2871	This	abstract[139]	giv[139]	coref	22-6[151_139]
20-2	2872-2880	gradient	abstract[139]	giv[139]	_	_
20-3	2881-2883	is	_	_	_	_
20-4	2884-2887	not	_	_	_	_
20-5	2888-2895	present	_	_	_	_
20-6	2896-2898	in	_	_	_	_
20-7	2899-2912	headache-free	person[140]	giv[140]	coref	28-24[201_140]
20-8	2913-2921	controls	person[140]	giv[140]	_	_
20-9	2922-2923	,	_	_	_	_
20-10	2924-2929	where	_	_	_	_
20-11	2930-2933	the	place[141]	giv[141]	coref	26-26[183_141]
20-12	2934-2938	most	place[141]	giv[141]	_	_
20-13	2939-2948	sensitive	place[141]	giv[141]	_	_
20-14	2949-2953	area	place[141]	giv[141]	_	_
20-15	2954-2957	was	_	_	_	_
20-16	2958-2965	located	_	_	_	_
20-17	2966-2968	in	_	_	_	_
20-18	2969-2972	the	object[142]	new[142]	_	_
20-19	2973-2983	mid-muscle	object[142]	new[142]	_	_
20-20	2984-2989	belly	object[142]	new[142]	_	_
20-21	2990-2991	.	_	_	_	_

#Text=The results of this study are similar to those previously described in other primary headaches , such as tension-type headache and unilateral migraine .
21-1	2992-2995	The	abstract[143]	giv[143]	_	_
21-2	2996-3003	results	abstract[143]	giv[143]	_	_
21-3	3004-3006	of	abstract[143]	giv[143]	_	_
21-4	3007-3011	this	abstract[143]|abstract[144]	giv[143]|giv[144]	coref	30-7[216_144]
21-5	3012-3017	study	abstract[143]|abstract[144]	giv[143]|giv[144]	_	_
21-6	3018-3021	are	_	_	_	_
21-7	3022-3029	similar	_	_	_	_
21-8	3030-3032	to	_	_	_	_
21-9	3033-3038	those	abstract	giv	_	_
21-10	3039-3049	previously	_	_	_	_
21-11	3050-3059	described	_	_	_	_
21-12	3060-3062	in	_	_	_	_
21-13	3063-3068	other	abstract[146]	giv[146]	coref	24-19[161_146]
21-14	3069-3076	primary	abstract[146]	giv[146]	_	_
21-15	3077-3086	headaches	abstract[146]	giv[146]	_	_
21-16	3087-3088	,	abstract[146]	giv[146]	_	_
21-17	3089-3093	such	abstract[146]	giv[146]	_	_
21-18	3094-3096	as	abstract[146]	giv[146]	_	_
21-19	3097-3109	tension-type	abstract[146]|abstract|abstract[148]	giv[146]|new|giv[148]	coref|coref	24-36[0_148]|24-36[0_148]
21-20	3110-3118	headache	abstract[146]|abstract[148]	giv[146]|giv[148]	_	_
21-21	3119-3122	and	abstract[146]	giv[146]	_	_
21-22	3123-3133	unilateral	abstract[146]|abstract[149]	giv[146]|giv[149]	_	_
21-23	3134-3142	migraine	abstract[146]|abstract[149]	giv[146]|giv[149]	_	_
21-24	3143-3144	.	_	_	_	_

#Text=To determine the mechanisms underlying the anterior-to-posterior gradient is beyond the scope of the current paper .
22-1	3145-3147	To	_	_	_	_
22-2	3148-3157	determine	_	_	_	_
22-3	3158-3161	the	abstract[150]	new[150]	_	_
22-4	3162-3172	mechanisms	abstract[150]	new[150]	_	_
22-5	3173-3183	underlying	_	_	_	_
22-6	3184-3187	the	abstract[151]	giv[151]	coref	25-3[166_151]
22-7	3188-3209	anterior-to-posterior	abstract[151]	giv[151]	_	_
22-8	3210-3218	gradient	abstract[151]	giv[151]	_	_
22-9	3219-3221	is	_	_	_	_
22-10	3222-3228	beyond	_	_	_	_
22-11	3229-3232	the	abstract[152]	new[152]	_	_
22-12	3233-3238	scope	abstract[152]	new[152]	_	_
22-13	3239-3241	of	abstract[152]	new[152]	_	_
22-14	3242-3245	the	abstract[152]|abstract[153]	new[152]|new[153]	_	_
22-15	3246-3253	current	abstract[152]|abstract[153]	new[152]|new[153]	_	_
22-16	3254-3259	paper	abstract[152]|abstract[153]	new[152]|new[153]	_	_
22-17	3260-3261	.	_	_	_	_

#Text=However , two hypotheses can be stated .
23-1	3262-3269	However	_	_	_	_
23-2	3270-3271	,	_	_	_	_
23-3	3272-3275	two	abstract[154]	new[154]	_	_
23-4	3276-3286	hypotheses	abstract[154]	new[154]	_	_
23-5	3287-3290	can	_	_	_	_
23-6	3291-3293	be	_	_	_	_
23-7	3294-3300	stated	_	_	_	_
23-8	3301-3302	.	_	_	_	_

#Text=First , sensitization of trigeminal pathways could generate a pressure pain hyperalgesic pattern with an anterior-to-posterior distribution in primary headaches , regardless of unilateral or bilateral location of the symptoms or the specific type of headache .
24-1	3303-3308	First	_	_	_	_
24-2	3309-3310	,	_	_	_	_
24-3	3311-3324	sensitization	abstract[155]	new[155]	coref	38-28[276_155]
24-4	3325-3327	of	abstract[155]	new[155]	_	_
24-5	3328-3338	trigeminal	abstract[155]|place[156]	new[155]|giv[156]	_	_
24-6	3339-3347	pathways	abstract[155]|place[156]	new[155]|giv[156]	_	_
24-7	3348-3353	could	_	_	_	_
24-8	3354-3362	generate	_	_	_	_
24-9	3363-3364	a	abstract[159]	new[159]	_	_
24-10	3365-3373	pressure	abstract|abstract[159]	giv|new[159]	coref	26-22
24-11	3374-3378	pain	abstract|abstract[159]	giv|new[159]	coref	26-23
24-12	3379-3391	hyperalgesic	abstract[159]	new[159]	_	_
24-13	3392-3399	pattern	abstract[159]	new[159]	_	_
24-14	3400-3404	with	_	_	_	_
24-15	3405-3407	an	abstract[160]	giv[160]	_	_
24-16	3408-3429	anterior-to-posterior	abstract[160]	giv[160]	_	_
24-17	3430-3442	distribution	abstract[160]	giv[160]	_	_
24-18	3443-3445	in	abstract[160]	giv[160]	_	_
24-19	3446-3453	primary	abstract[160]|abstract[161]	giv[160]|giv[161]	coref	25-28[0_161]
24-20	3454-3463	headaches	abstract[160]|abstract[161]	giv[160]|giv[161]	_	_
24-21	3464-3465	,	_	_	_	_
24-22	3466-3476	regardless	_	_	_	_
24-23	3477-3479	of	_	_	_	_
24-24	3480-3490	unilateral	place[162]	new[162]	_	_
24-25	3491-3493	or	place[162]	new[162]	_	_
24-26	3494-3503	bilateral	place[162]	new[162]	_	_
24-27	3504-3512	location	place[162]	new[162]	_	_
24-28	3513-3515	of	place[162]	new[162]	_	_
24-29	3516-3519	the	place[162]|abstract[163]	new[162]|giv[163]	_	_
24-30	3520-3528	symptoms	place[162]|abstract[163]	new[162]|giv[163]	_	_
24-31	3529-3531	or	place[162]|abstract[163]	new[162]|giv[163]	_	_
24-32	3532-3535	the	place[162]|abstract[163]|abstract[164]	new[162]|giv[163]|new[164]	_	_
24-33	3536-3544	specific	place[162]|abstract[163]|abstract[164]	new[162]|giv[163]|new[164]	_	_
24-34	3545-3549	type	place[162]|abstract[163]|abstract[164]	new[162]|giv[163]|new[164]	_	_
24-35	3550-3552	of	place[162]|abstract[163]|abstract[164]	new[162]|giv[163]|new[164]	_	_
24-36	3553-3561	headache	place[162]|abstract[163]|abstract[164]|abstract	new[162]|giv[163]|new[164]|giv	coref	28-21
24-37	3562-3563	.	_	_	_	_

#Text=Secondly , an anterior-to-posterior gradient could be also related to different distribution of muscle nociceptors between the different areas of the temporalis muscle that could predispose to headaches , but this cannot be confirmed until histological studies are conducted .
25-1	3564-3572	Secondly	_	_	_	_
25-2	3573-3574	,	_	_	_	_
25-3	3575-3577	an	abstract[166]	giv[166]	coref	35-15[258_166]
25-4	3578-3599	anterior-to-posterior	abstract[166]	giv[166]	_	_
25-5	3600-3608	gradient	abstract[166]	giv[166]	_	_
25-6	3609-3614	could	_	_	_	_
25-7	3615-3617	be	_	_	_	_
25-8	3618-3622	also	_	_	_	_
25-9	3623-3630	related	_	_	_	_
25-10	3631-3633	to	_	_	_	_
25-11	3634-3643	different	abstract[167]	new[167]	ana	25-31[0_167]
25-12	3644-3656	distribution	abstract[167]	new[167]	_	_
25-13	3657-3659	of	abstract[167]	new[167]	_	_
25-14	3660-3666	muscle	abstract[167]|object|abstract[169]	new[167]|giv|new[169]	coref|coref	25-21[171_0]|25-21[171_0]
25-15	3667-3678	nociceptors	abstract[167]|abstract[169]	new[167]|new[169]	_	_
25-16	3679-3686	between	abstract[167]	new[167]	_	_
25-17	3687-3690	the	abstract[167]|place[170]	new[167]|new[170]	_	_
25-18	3691-3700	different	abstract[167]|place[170]	new[167]|new[170]	_	_
25-19	3701-3706	areas	abstract[167]|place[170]	new[167]|new[170]	_	_
25-20	3707-3709	of	abstract[167]|place[170]	new[167]|new[170]	_	_
25-21	3710-3713	the	abstract[167]|place[170]|object[171]	new[167]|new[170]|giv[171]	_	_
25-22	3714-3724	temporalis	abstract[167]|place[170]|object[171]	new[167]|new[170]|giv[171]	_	_
25-23	3725-3731	muscle	abstract[167]|place[170]|object[171]	new[167]|new[170]|giv[171]	_	_
25-24	3732-3736	that	_	_	_	_
25-25	3737-3742	could	_	_	_	_
25-26	3743-3753	predispose	_	_	_	_
25-27	3754-3756	to	_	_	_	_
25-28	3757-3766	headaches	abstract	giv	coref	27-23[192_0]
25-29	3767-3768	,	_	_	_	_
25-30	3769-3772	but	_	_	_	_
25-31	3773-3777	this	abstract	giv	_	_
25-32	3778-3784	cannot	_	_	_	_
25-33	3785-3787	be	_	_	_	_
25-34	3788-3797	confirmed	_	_	_	_
25-35	3798-3803	until	_	_	_	_
25-36	3804-3816	histological	event[174]	giv[174]	coref	28-18[198_174]
25-37	3817-3824	studies	event[174]	giv[174]	_	_
25-38	3825-3828	are	_	_	_	_
25-39	3829-3838	conducted	_	_	_	_
25-40	3839-3840	.	_	_	_	_

#Text=Additionally , we also found that the levels of anxiety and depression do not seem to have a significant influence on pressure pain hyperalgesia within the trigeminal area in men with episodic CH .
26-1	3841-3853	Additionally	_	_	_	_
26-2	3854-3855	,	_	_	_	_
26-3	3856-3858	we	person	giv	ana	30-1
26-4	3859-3863	also	_	_	_	_
26-5	3864-3869	found	_	_	_	_
26-6	3870-3874	that	_	_	_	_
26-7	3875-3878	the	abstract[176]	new[176]	_	_
26-8	3879-3885	levels	abstract[176]	new[176]	_	_
26-9	3886-3888	of	abstract[176]	new[176]	_	_
26-10	3889-3896	anxiety	abstract[176]|abstract	new[176]|new	_	_
26-11	3897-3900	and	abstract[176]	new[176]	_	_
26-12	3901-3911	depression	abstract[176]|abstract	new[176]|new	_	_
26-13	3912-3914	do	_	_	_	_
26-14	3915-3918	not	_	_	_	_
26-15	3919-3923	seem	_	_	_	_
26-16	3924-3926	to	_	_	_	_
26-17	3927-3931	have	_	_	_	_
26-18	3932-3933	a	abstract[179]	new[179]	_	_
26-19	3934-3945	significant	abstract[179]	new[179]	_	_
26-20	3946-3955	influence	abstract[179]	new[179]	_	_
26-21	3956-3958	on	abstract[179]	new[179]	_	_
26-22	3959-3967	pressure	abstract[179]|abstract|abstract[182]	new[179]|giv|giv[182]	coref|coref	28-12|28-12
26-23	3968-3972	pain	abstract[179]|abstract|abstract[182]	new[179]|giv|giv[182]	coref	27-21
26-24	3973-3985	hyperalgesia	abstract[179]|abstract[182]	new[179]|giv[182]	_	_
26-25	3986-3992	within	abstract[179]|abstract[182]	new[179]|giv[182]	_	_
26-26	3993-3996	the	abstract[179]|abstract[182]|place[183]	new[179]|giv[182]|giv[183]	coref	29-13[208_183]
26-27	3997-4007	trigeminal	abstract[179]|abstract[182]|place[183]	new[179]|giv[182]|giv[183]	_	_
26-28	4008-4012	area	abstract[179]|abstract[182]|place[183]	new[179]|giv[182]|giv[183]	_	_
26-29	4013-4015	in	abstract[179]|abstract[182]|place[183]	new[179]|giv[182]|giv[183]	_	_
26-30	4016-4019	men	abstract[179]|abstract[182]|place[183]|person[184]	new[179]|giv[182]|giv[183]|new[184]	coref	31-9[219_184]
26-31	4020-4024	with	abstract[179]|abstract[182]|place[183]|person[184]	new[179]|giv[182]|giv[183]|new[184]	_	_
26-32	4025-4033	episodic	abstract[179]|abstract[182]|place[183]|person[184]|abstract[185]	new[179]|giv[182]|giv[183]|new[184]|giv[185]	coref	29-28[0_185]
26-33	4034-4036	CH	abstract[179]|abstract[182]|place[183]|person[184]|abstract[185]	new[179]|giv[182]|giv[183]|new[184]|giv[185]	_	_
26-34	4037-4038	.	_	_	_	_

#Text=It would be interesting to investigate other potential psychological factors related to the observed anterior-to-posterior distribution of sensitivity to pressure pain in primary headaches .
27-1	4039-4041	It	abstract	new	cata	27-1[0_187]
27-2	4042-4047	would	_	_	_	_
27-3	4048-4050	be	_	_	_	_
27-4	4051-4062	interesting	_	_	_	_
27-5	4063-4065	to	abstract[187]	new[187]	_	_
27-6	4066-4077	investigate	abstract[187]	new[187]	_	_
27-7	4078-4083	other	abstract[187]|abstract[188]	new[187]|new[188]	_	_
27-8	4084-4093	potential	abstract[187]|abstract[188]	new[187]|new[188]	_	_
27-9	4094-4107	psychological	abstract[187]|abstract[188]	new[187]|new[188]	_	_
27-10	4108-4115	factors	abstract[187]|abstract[188]	new[187]|new[188]	_	_
27-11	4116-4123	related	_	_	_	_
27-12	4124-4126	to	_	_	_	_
27-13	4127-4130	the	abstract[189]	new[189]	_	_
27-14	4131-4139	observed	abstract[189]	new[189]	_	_
27-15	4140-4161	anterior-to-posterior	abstract[189]	new[189]	_	_
27-16	4162-4174	distribution	abstract[189]	new[189]	_	_
27-17	4175-4177	of	abstract[189]	new[189]	_	_
27-18	4178-4189	sensitivity	abstract[189]|abstract[190]	new[189]|giv[190]	coref	28-10[195_190]
27-19	4190-4192	to	abstract[189]|abstract[190]	new[189]|giv[190]	_	_
27-20	4193-4201	pressure	abstract[189]|abstract[190]	new[189]|giv[190]	_	_
27-21	4202-4206	pain	abstract[189]|abstract[190]|abstract	new[189]|giv[190]|giv	coref	28-12[197_0]
27-22	4207-4209	in	_	_	_	_
27-23	4210-4217	primary	abstract[192]	giv[192]	_	_
27-24	4218-4227	headaches	abstract[192]	giv[192]	_	_
27-25	4228-4229	.	_	_	_	_

#Text=In fact , differences in the spatial distribution of sensitivity to pressure pain should be considered in future studies comparing headache populations and headache-free controls , since taking the same point as a reference could be biased .
28-1	4230-4232	In	_	_	_	_
28-2	4233-4237	fact	_	_	_	_
28-3	4238-4239	,	_	_	_	_
28-4	4240-4251	differences	abstract[193]	new[193]	_	_
28-5	4252-4254	in	abstract[193]	new[193]	_	_
28-6	4255-4258	the	abstract[193]|abstract[194]	new[193]|new[194]	_	_
28-7	4259-4266	spatial	abstract[193]|abstract[194]	new[193]|new[194]	_	_
28-8	4267-4279	distribution	abstract[193]|abstract[194]	new[193]|new[194]	_	_
28-9	4280-4282	of	abstract[193]|abstract[194]	new[193]|new[194]	_	_
28-10	4283-4294	sensitivity	abstract[193]|abstract[194]|abstract[195]	new[193]|new[194]|giv[195]	coref	33-23[240_195]
28-11	4295-4297	to	abstract[193]|abstract[194]|abstract[195]	new[193]|new[194]|giv[195]	_	_
28-12	4298-4306	pressure	abstract[193]|abstract[194]|abstract[195]|abstract|abstract[197]	new[193]|new[194]|giv[195]|giv|giv[197]	coref|coref|coref|coref	29-10|29-10[207_197]|29-10|29-10[207_197]
28-13	4307-4311	pain	abstract[193]|abstract[194]|abstract[195]|abstract[197]	new[193]|new[194]|giv[195]|giv[197]	_	_
28-14	4312-4318	should	_	_	_	_
28-15	4319-4321	be	_	_	_	_
28-16	4322-4332	considered	_	_	_	_
28-17	4333-4335	in	_	_	_	_
28-18	4336-4342	future	event[198]	giv[198]	coref	36-1[263_198]
28-19	4343-4350	studies	event[198]	giv[198]	_	_
28-20	4351-4360	comparing	_	_	_	_
28-21	4361-4369	headache	abstract|abstract[200]	giv|new[200]	_	_
28-22	4370-4381	populations	abstract[200]	new[200]	_	_
28-23	4382-4385	and	_	_	_	_
28-24	4386-4399	headache-free	person[201]	giv[201]	_	_
28-25	4400-4408	controls	person[201]	giv[201]	_	_
28-26	4409-4410	,	_	_	_	_
28-27	4411-4416	since	_	_	_	_
28-28	4417-4423	taking	_	_	_	_
28-29	4424-4427	the	place[202]	new[202]	_	_
28-30	4428-4432	same	place[202]	new[202]	_	_
28-31	4433-4438	point	place[202]	new[202]	_	_
28-32	4439-4441	as	_	_	_	_
28-33	4442-4443	a	abstract[203]	new[203]	_	_
28-34	4444-4453	reference	abstract[203]	new[203]	_	_
28-35	4454-4459	could	_	_	_	_
28-36	4460-4462	be	_	_	_	_
28-37	4463-4469	biased	_	_	_	_
28-38	4470-4471	.	_	_	_	_

#Text=In addition , changes in the spatial distribution of pressure pain within the trigeminal area could be used to monitor the effects of treatment in individuals with CH .
29-1	4472-4474	In	_	_	_	_
29-2	4475-4483	addition	_	_	_	_
29-3	4484-4485	,	_	_	_	_
29-4	4486-4493	changes	abstract[204]	new[204]	_	_
29-5	4494-4496	in	abstract[204]	new[204]	_	_
29-6	4497-4500	the	abstract[204]|abstract[205]	new[204]|new[205]	_	_
29-7	4501-4508	spatial	abstract[204]|abstract[205]	new[204]|new[205]	_	_
29-8	4509-4521	distribution	abstract[204]|abstract[205]	new[204]|new[205]	_	_
29-9	4522-4524	of	abstract[204]|abstract[205]	new[204]|new[205]	_	_
29-10	4525-4533	pressure	abstract[204]|abstract[205]|abstract|abstract[207]	new[204]|new[205]|giv|giv[207]	coref|coref|coref|coref	33-23|33-24[0_207]|33-23|33-24[0_207]
29-11	4534-4538	pain	abstract[204]|abstract[205]|abstract[207]	new[204]|new[205]|giv[207]	_	_
29-12	4539-4545	within	abstract[204]|abstract[205]|abstract[207]	new[204]|new[205]|giv[207]	_	_
29-13	4546-4549	the	abstract[204]|abstract[205]|abstract[207]|place[208]	new[204]|new[205]|giv[207]|giv[208]	_	_
29-14	4550-4560	trigeminal	abstract[204]|abstract[205]|abstract[207]|place[208]	new[204]|new[205]|giv[207]|giv[208]	_	_
29-15	4561-4565	area	abstract[204]|abstract[205]|abstract[207]|place[208]	new[204]|new[205]|giv[207]|giv[208]	_	_
29-16	4566-4571	could	_	_	_	_
29-17	4572-4574	be	_	_	_	_
29-18	4575-4579	used	_	_	_	_
29-19	4580-4582	to	_	_	_	_
29-20	4583-4590	monitor	_	_	_	_
29-21	4591-4594	the	abstract[209]	new[209]	_	_
29-22	4595-4602	effects	abstract[209]	new[209]	_	_
29-23	4603-4605	of	abstract[209]	new[209]	_	_
29-24	4606-4615	treatment	abstract[209]|event[210]	new[209]|new[210]	_	_
29-25	4616-4618	in	abstract[209]|event[210]	new[209]|new[210]	_	_
29-26	4619-4630	individuals	abstract[209]|event[210]|person[211]	new[209]|new[210]|giv[211]	_	_
29-27	4631-4635	with	abstract[209]|event[210]|person[211]	new[209]|new[210]|giv[211]	_	_
29-28	4636-4638	CH	abstract[209]|event[210]|person[211]|abstract	new[209]|new[210]|giv[211]|giv	coref	31-11[220_0]
29-29	4639-4640	.	_	_	_	_

#Text=We must recognize some limitations of our study .
30-1	4641-4643	We	person	giv	ana	30-7
30-2	4644-4648	must	_	_	_	_
30-3	4649-4658	recognize	_	_	_	_
30-4	4659-4663	some	abstract[214]	new[214]	_	_
30-5	4664-4675	limitations	abstract[214]	new[214]	_	_
30-6	4676-4678	of	abstract[214]	new[214]	_	_
30-7	4679-4682	our	abstract[214]|person|abstract[216]	new[214]|giv|giv[216]	ana|ana	31-3|31-3
30-8	4683-4688	study	abstract[214]|abstract[216]	new[214]|giv[216]	_	_
30-9	4689-4690	.	_	_	_	_

#Text=First , our sample was only comprised of men with episodic CH in a remission phase .
31-1	4691-4696	First	_	_	_	_
31-2	4697-4698	,	_	_	_	_
31-3	4699-4702	our	person|object[218]	giv|new[218]	ana|coref|ana|coref	32-3|33-8[234_218]|32-3|33-8[234_218]
31-4	4703-4709	sample	object[218]	new[218]	_	_
31-5	4710-4713	was	_	_	_	_
31-6	4714-4718	only	_	_	_	_
31-7	4719-4728	comprised	_	_	_	_
31-8	4729-4731	of	_	_	_	_
31-9	4732-4735	men	person[219]	giv[219]	coref	32-13[228_219]
31-10	4736-4740	with	person[219]	giv[219]	_	_
31-11	4741-4749	episodic	person[219]|abstract[220]	giv[219]|giv[220]	coref	32-10[0_220]
31-12	4750-4752	CH	person[219]|abstract[220]	giv[219]|giv[220]	_	_
31-13	4753-4755	in	_	_	_	_
31-14	4756-4757	a	abstract[222]	giv[222]	coref	32-23[231_222]
31-15	4758-4767	remission	abstract|abstract[222]	giv|giv[222]	_	_
31-16	4768-4773	phase	abstract[222]	giv[222]	_	_
31-17	4774-4775	.	_	_	_	_

#Text=Therefore , we cannot draw conclusions concerning women with CH , or men with chronic CH , or with episodic CH in an active phase .
32-1	4776-4785	Therefore	_	_	_	_
32-2	4786-4787	,	_	_	_	_
32-3	4788-4790	we	person	giv	ana	33-8
32-4	4791-4797	cannot	_	_	_	_
32-5	4798-4802	draw	_	_	_	_
32-6	4803-4814	conclusions	abstract	new	_	_
32-7	4815-4825	concerning	_	_	_	_
32-8	4826-4831	women	person[225]|person[226]	new[225]|new[226]	ana|ana	33-16[0_226]|33-16[0_226]
32-9	4832-4836	with	person[225]|person[226]	new[225]|new[226]	_	_
32-10	4837-4839	CH	person[225]|person[226]|abstract	new[225]|new[226]|giv	coref	32-15[229_0]
32-11	4840-4841	,	person[226]	new[226]	_	_
32-12	4842-4844	or	person[226]	new[226]	_	_
32-13	4845-4848	men	person[226]|person[228]	new[226]|giv[228]	coref	35-20[0_228]
32-14	4849-4853	with	person[226]|person[228]	new[226]|giv[228]	_	_
32-15	4854-4861	chronic	person[226]|person[228]|abstract[229]	new[226]|giv[228]|giv[229]	coref	32-20[230_229]
32-16	4862-4864	CH	person[226]|person[228]|abstract[229]	new[226]|giv[228]|giv[229]	_	_
32-17	4865-4866	,	_	_	_	_
32-18	4867-4869	or	_	_	_	_
32-19	4870-4874	with	_	_	_	_
32-20	4875-4883	episodic	abstract[230]	giv[230]	coref	34-33[0_230]
32-21	4884-4886	CH	abstract[230]	giv[230]	_	_
32-22	4887-4889	in	abstract[230]	giv[230]	_	_
32-23	4890-4892	an	abstract[230]|abstract[231]	giv[230]|giv[231]	coref	33-32[242_231]
32-24	4893-4899	active	abstract[230]|abstract[231]	giv[230]|giv[231]	_	_
32-25	4900-4905	phase	abstract[230]|abstract[231]	giv[230]|giv[231]	_	_
32-26	4906-4907	.	_	_	_	_

#Text=Secondly , depressive and anxiety levels of our sample were relatively low , thus , their potential role in spatial distribution of pressure pain sensitivity should be considered with caution at this stage .
33-1	4908-4916	Secondly	_	_	_	_
33-2	4917-4918	,	_	_	_	_
33-3	4919-4929	depressive	abstract[232]	new[232]	_	_
33-4	4930-4933	and	abstract[232]	new[232]	_	_
33-5	4934-4941	anxiety	abstract[232]	new[232]	_	_
33-6	4942-4948	levels	abstract[232]	new[232]	_	_
33-7	4949-4951	of	abstract[232]	new[232]	_	_
33-8	4952-4955	our	abstract[232]|person|person[234]	new[232]|giv|giv[234]	ana|ana	34-3|34-3
33-9	4956-4962	sample	abstract[232]|person[234]	new[232]|giv[234]	_	_
33-10	4963-4967	were	_	_	_	_
33-11	4968-4978	relatively	_	_	_	_
33-12	4979-4982	low	_	_	_	_
33-13	4983-4984	,	_	_	_	_
33-14	4985-4989	thus	_	_	_	_
33-15	4990-4991	,	_	_	_	_
33-16	4992-4997	their	person|abstract[236]	giv|new[236]	_	_
33-17	4998-5007	potential	abstract[236]	new[236]	_	_
33-18	5008-5012	role	abstract[236]	new[236]	_	_
33-19	5013-5015	in	abstract[236]	new[236]	_	_
33-20	5016-5023	spatial	abstract[236]|abstract[237]	new[236]|new[237]	_	_
33-21	5024-5036	distribution	abstract[236]|abstract[237]	new[236]|new[237]	_	_
33-22	5037-5039	of	abstract[236]|abstract[237]	new[236]|new[237]	_	_
33-23	5040-5048	pressure	abstract[236]|abstract[237]|abstract|abstract[240]	new[236]|new[237]|giv|giv[240]	coref|coref|coref|coref	34-24|34-24[250_240]|34-24|34-24[250_240]
33-24	5049-5053	pain	abstract[236]|abstract[237]|abstract|abstract[240]	new[236]|new[237]|giv|giv[240]	coref	34-25
33-25	5054-5065	sensitivity	abstract[236]|abstract[237]|abstract[240]	new[236]|new[237]|giv[240]	_	_
33-26	5066-5072	should	_	_	_	_
33-27	5073-5075	be	_	_	_	_
33-28	5076-5086	considered	_	_	_	_
33-29	5087-5091	with	_	_	_	_
33-30	5092-5099	caution	abstract[241]	new[241]	_	_
33-31	5100-5102	at	abstract[241]	new[241]	_	_
33-32	5103-5107	this	abstract[241]|abstract[242]	new[241]|giv[242]	_	_
33-33	5108-5113	stage	abstract[241]|abstract[242]	new[241]|giv[242]	_	_
33-34	5114-5115	.	_	_	_	_

#Text=Thirdly , we used a cross-sectional design , which does not permit to determine a cause and effect relationship between spatial distribution of pressure pain sensitivity and the development or maintenance of CH .
34-1	5116-5123	Thirdly	_	_	_	_
34-2	5124-5125	,	_	_	_	_
34-3	5126-5128	we	person	giv	ana	37-3
34-4	5129-5133	used	_	_	_	_
34-5	5134-5135	a	abstract[244]	new[244]	_	_
34-6	5136-5151	cross-sectional	abstract[244]	new[244]	_	_
34-7	5152-5158	design	abstract[244]	new[244]	_	_
34-8	5159-5160	,	_	_	_	_
34-9	5161-5166	which	_	_	_	_
34-10	5167-5171	does	_	_	_	_
34-11	5172-5175	not	_	_	_	_
34-12	5176-5182	permit	_	_	_	_
34-13	5183-5185	to	_	_	_	_
34-14	5186-5195	determine	_	_	_	_
34-15	5196-5197	a	abstract[245]	new[245]	_	_
34-16	5198-5203	cause	abstract[245]	new[245]	_	_
34-17	5204-5207	and	_	_	_	_
34-18	5208-5214	effect	_	_	_	_
34-19	5215-5227	relationship	abstract[246]	new[246]	_	_
34-20	5228-5235	between	abstract[246]	new[246]	_	_
34-21	5236-5243	spatial	abstract[246]|abstract[247]	new[246]|new[247]	_	_
34-22	5244-5256	distribution	abstract[246]|abstract[247]	new[246]|new[247]	_	_
34-23	5257-5259	of	abstract[246]|abstract[247]	new[246]|new[247]	_	_
34-24	5260-5268	pressure	abstract[246]|abstract[247]|abstract|abstract[250]	new[246]|new[247]|giv|giv[250]	_	_
34-25	5269-5273	pain	abstract[246]|abstract[247]|abstract|abstract[250]	new[246]|new[247]|giv|giv[250]	coref	35-11
34-26	5274-5285	sensitivity	abstract[246]|abstract[247]|abstract[250]	new[246]|new[247]|giv[250]	_	_
34-27	5286-5289	and	abstract[246]|abstract[247]	new[246]|new[247]	_	_
34-28	5290-5293	the	abstract[246]|abstract[247]|event[251]	new[246]|new[247]|new[251]	_	_
34-29	5294-5305	development	abstract[246]|abstract[247]|event[251]	new[246]|new[247]|new[251]	_	_
34-30	5306-5308	or	abstract[246]|abstract[247]	new[246]|new[247]	_	_
34-31	5309-5320	maintenance	abstract[246]|abstract[247]|abstract[252]	new[246]|new[247]|new[252]	_	_
34-32	5321-5323	of	abstract[246]|abstract[247]|abstract[252]	new[246]|new[247]|new[252]	_	_
34-33	5324-5326	CH	abstract[246]|abstract[247]|abstract[252]|abstract	new[246]|new[247]|new[252]|giv	coref	35-22
34-34	5327-5328	.	_	_	_	_

#Text=However , the fact that headache-free control subjects showed heterogeneous pain maps suggests that the anterior-to-posterior gradient observed in men with CH is related to the presence of pain .
35-1	5329-5336	However	_	_	_	_
35-2	5337-5338	,	_	_	_	_
35-3	5339-5342	the	abstract[254]	new[254]	_	_
35-4	5343-5347	fact	abstract[254]	new[254]	_	_
35-5	5348-5352	that	abstract[254]	new[254]	_	_
35-6	5353-5366	headache-free	abstract[254]|person[255]	new[254]|new[255]	_	_
35-7	5367-5374	control	abstract[254]|person[255]	new[254]|new[255]	_	_
35-8	5375-5383	subjects	abstract[254]|person[255]	new[254]|new[255]	_	_
35-9	5384-5390	showed	abstract[254]	new[254]	_	_
35-10	5391-5404	heterogeneous	abstract[254]|object[257]	new[254]|giv[257]	_	_
35-11	5405-5409	pain	abstract[254]|abstract|object[257]	new[254]|giv|giv[257]	coref	35-29
35-12	5410-5414	maps	abstract[254]|object[257]	new[254]|giv[257]	_	_
35-13	5415-5423	suggests	_	_	_	_
35-14	5424-5428	that	_	_	_	_
35-15	5429-5432	the	abstract[258]	giv[258]	_	_
35-16	5433-5454	anterior-to-posterior	abstract[258]	giv[258]	_	_
35-17	5455-5463	gradient	abstract[258]	giv[258]	_	_
35-18	5464-5472	observed	_	_	_	_
35-19	5473-5475	in	_	_	_	_
35-20	5476-5479	men	person	giv	_	_
35-21	5480-5484	with	_	_	_	_
35-22	5485-5487	CH	abstract	giv	coref	38-31
35-23	5488-5490	is	_	_	_	_
35-24	5491-5498	related	_	_	_	_
35-25	5499-5501	to	_	_	_	_
35-26	5502-5505	the	abstract[261]	new[261]	_	_
35-27	5506-5514	presence	abstract[261]	new[261]	_	_
35-28	5515-5517	of	abstract[261]	new[261]	_	_
35-29	5518-5522	pain	abstract[261]|abstract	new[261]|giv	coref	38-14
35-30	5523-5524	.	_	_	_	_

#Text=Longitudinal studies are needed to clarify this hypothesis .
36-1	5525-5537	Longitudinal	event[263]	giv[263]	coref	38-20[274_263]
36-2	5538-5545	studies	event[263]	giv[263]	_	_
36-3	5546-5549	are	_	_	_	_
36-4	5550-5556	needed	_	_	_	_
36-5	5557-5559	to	_	_	_	_
36-6	5560-5567	clarify	_	_	_	_
36-7	5568-5572	this	abstract[264]	new[264]	_	_
36-8	5573-5583	hypothesis	abstract[264]	new[264]	_	_
36-9	5584-5585	.	_	_	_	_

#Text=Finally , we only assessed static outcomes of nociception , i. e. , PPT .
37-1	5586-5593	Finally	_	_	_	_
37-2	5594-5595	,	_	_	_	_
37-3	5596-5598	we	person	giv	_	_
37-4	5599-5603	only	_	_	_	_
37-5	5604-5612	assessed	_	_	_	_
37-6	5613-5619	static	abstract[266]	new[266]	coref	38-3[269_266]
37-7	5620-5628	outcomes	abstract[266]	new[266]	_	_
37-8	5629-5631	of	abstract[266]	new[266]	_	_
37-9	5632-5643	nociception	abstract[266]|abstract	new[266]|new	_	_
37-10	5644-5645	,	abstract[266]	new[266]	_	_
37-11	5646-5648	i.	abstract[266]	new[266]	_	_
37-12	5649-5651	e.	abstract[266]	new[266]	_	_
37-13	5652-5653	,	abstract[266]	new[266]	_	_
37-14	5654-5657	PPT	abstract[266]|abstract	new[266]|new	_	_
37-15	5658-5659	.	_	_	_	_

#Text=Thus , dynamic outcomes such as temporal summation , wind-up , or conditioned pain modulation should be used in future studies to further characterize the presence of central sensitization in CH .
38-1	5660-5664	Thus	_	_	_	_
38-2	5665-5666	,	_	_	_	_
38-3	5667-5674	dynamic	abstract[269]	giv[269]	_	_
38-4	5675-5683	outcomes	abstract[269]	giv[269]	_	_
38-5	5684-5688	such	abstract[269]	giv[269]	_	_
38-6	5689-5691	as	abstract[269]	giv[269]	_	_
38-7	5692-5700	temporal	abstract[269]|abstract[270]	giv[269]|new[270]	_	_
38-8	5701-5710	summation	abstract[269]|abstract[270]	giv[269]|new[270]	_	_
38-9	5711-5712	,	abstract[269]	giv[269]	_	_
38-10	5713-5720	wind-up	abstract[269]|event	giv[269]|new	_	_
38-11	5721-5722	,	abstract[269]	giv[269]	_	_
38-12	5723-5725	or	abstract[269]	giv[269]	_	_
38-13	5726-5737	conditioned	abstract[269]|abstract[273]	giv[269]|new[273]	_	_
38-14	5738-5742	pain	abstract[269]|abstract|abstract[273]	giv[269]|giv|new[273]	_	_
38-15	5743-5753	modulation	abstract[269]|abstract[273]	giv[269]|new[273]	_	_
38-16	5754-5760	should	_	_	_	_
38-17	5761-5763	be	_	_	_	_
38-18	5764-5768	used	_	_	_	_
38-19	5769-5771	in	_	_	_	_
38-20	5772-5778	future	event[274]	giv[274]	_	_
38-21	5779-5786	studies	event[274]	giv[274]	_	_
38-22	5787-5789	to	_	_	_	_
38-23	5790-5797	further	_	_	_	_
38-24	5798-5810	characterize	_	_	_	_
38-25	5811-5814	the	abstract[275]	new[275]	_	_
38-26	5815-5823	presence	abstract[275]	new[275]	_	_
38-27	5824-5826	of	abstract[275]	new[275]	_	_
38-28	5827-5834	central	abstract[275]|abstract[276]	new[275]|giv[276]	_	_
38-29	5835-5848	sensitization	abstract[275]|abstract[276]	new[275]|giv[276]	_	_
38-30	5849-5851	in	abstract[275]|abstract[276]	new[275]|giv[276]	_	_
38-31	5852-5854	CH	abstract[275]|abstract[276]|abstract	new[275]|giv[276]|giv	_	_
38-32	5855-5856	.	_	_	_	_
